Corpus overview


Overview

MeSH Disease

Human Phenotype

Cough (74)

Fever (63)

Pneumonia (29)

Fatigue (27)

Diarrhea (12)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 74
    records per page




    Clinical course and management of 73 hospitalized moderate patients with COVID-19 outside Wuhan

    Authors: Xiaojuan Peng; Qi Qi Liu; Zhaolin Chen; Guiyan Wen; Qing Li; Yanfang Chen; Jie Xiong; Xinzhou Meng; Yuanjin Ding; Ying Shi; Shaohui Tang

    doi:10.21203/rs.3.rs-76135/v1 Date: 2020-09-11 Source: ResearchSquare

    Background: Moderate cases account for the majority in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD and can also progress to severe/critical condition. Here, we investigated the clinical course and management of hospitalized moderate SARS-CoV-2 patients.Methods: The medical records and follow-up data were analyzed from the SARS-CoV-2 patients outside Wuhan.Results: A total of 73 moderate patients (38 men, 35 women) were included, with median age TRANS of 47.0 (38.5-57.5) years. Among them, only one patient (1.4%) died using active treatment to improve symptoms. The median duration of the four main symptoms cough HP, fever HP fever MESHD, chest tightness HP chest tightness MESHD, and fatigue HP fatigue MESHD were about 1-2 weeks; the median duration of the positive nucleic acid test (NAT) results for SARS-CoV-2 was slightly more than 2 weeks; the median hospitalization time was almost four weeks in 72 moderate survivors. The duration of cough HP cough MESHD and fever HP fever MESHD was positively correlated with the duration of the positive NAT results. On admission, 50% had lymphopenia HP lymphopenia MESHD; less than 30% had abnormal blood SERO biochemistry findings involving hyperglycemia HP hyperglycemia MESHD, liver function and myocardial enzymes. At discharge, the laboratory indexes were substantially improved. Two weeks after discharge, 5.6% survivors experienced a recurrence of the positive NAT results. Conclusions: Moderate SARS-CoV-2 patients have a good prognosis by the active treatment. After discharge, it is necessary that moderate survivors undergo at least a 2-week collective medical observation in quarantine places, which can identify and treat a proportion of patients with re-positive NAT results and to prevent the spread of the potential sources of infection MESHD.

    Clinical Characteristics of Severe Covid Pneumonia HP: Exploring New Trends in ICU

    Authors: Aftab Akhtar; Sheher Bano; Ahtesham Iqbal; Moazma Ramzan; Aayesha Qadeer; Syed Waqar Hussain; Anam Saleem; Omair-ul-Haq Lodhi; Sana Zubair; Abdul Hameed kiani

    doi:10.21203/rs.3.rs-69224/v1 Date: 2020-08-31 Source: ResearchSquare

    Background: In late December 2019, Covid-19 emerged as clusters of pneumonia HP pneumonia MESHD of unknown cause in a province of china, Wuhan. Etiological agent was identified as novel coronavirus that resembles severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East Respiratory syndrome coronavirus (MERS-CoV) MESHD and has zoonotic transmission TRANS. Covid pneumonia HP can remain asymptomatic TRANS, present as mild infection, severe HP infection, severe MESHD pneumonia HP pneumonia MESHD or respiratory failure HP respiratory failure MESHD. Diagnosis is based on rRT-PCR carried out on respiratory secretions. Covid related mortality exceeds 50% once patient requires ICU admission. Objective: To study the characteristics of ICU population admitted to ICU of Shifa International hospital.Results: we prospectively analysed 74 patients which included 43.3% females TRANS and 56.7% males TRANS. Commonest symptoms were shortness of breath MESHD (94.5%), fever HP fever MESHD (74.3%) and cough HP (74.3%). Most of our study population consisted of non-smokers (79.7%) and had hypertension HP hypertension MESHD (59.4%) followed by diabetes MESHD (47.2%). Hydroxychloroquine (HCQ) and azithromycin combination is superior to hydroxychloroquine and doxycycline in reducing mortality (p=0.023) whereas Doxycycline alone resulted in increased mortality (p=0.009). Those who did not require antibiotics or required only narrow spectrum antibiotics had increased survival and reduced requirement of invasive mechanical ventilation (p=< 0.0001). in our study population, (44.9%) developed acute kidney injury HP acute kidney injury MESHD, 2.7% needed re-intubations 10.8% developed surgical emphysema HP emphysema MESHD and 2.7 % thromboembolic MESHD events despite full anticoagulation. ICU mortality was 41.8% and was higher in females TRANS (59.4%, p=0.008), those who had SOFA score > 3.5 at time of admission, raised D-Dimers > 931 ng/ml, NLR > 9.2. It was further high in those who required invasive mechanical ventilation and vasopressor support (58.1% mortality p=< 0.001). ICU stay was more prolonged in those requiring invasive mechanical ventilation as compared to those who did not. (23 days vs 6 days, p=0.001). Mean plateau pressure was 19.6 ± 7.6; mean Driving pressures 14.4 ± 4.6; mean PaO2/FiO2 150.7 ± 73.9; mean SPO2/FiO2 173.9 ± 106.9; mean PEEP was 8.2 ±4.33.Conclusion: We concluded that severe covid pneumonia HP pneumonia MESHD is common amongst males TRANS, non-smokers those who had comorbid. HCQ and azithromycin combination is superior to combination of HCQ and doxycycline or doxycycline alone and QT prolongation MESHD is a rare complication. Baseline NLR, APACHI II, SOFA, SAPS II, NUTRIC scores, D-Dimers, invasive ventilation and vasopressor support are important tools to predict ICU mortality. Invasive mechanical ventilation carries higher mortality and associated with more prolonged ICU stay. AKI is most common complication followed by shock HP and surgical emphysema HP emphysema MESHD. CRP, Ferritin levels has no impact on outcome.

    A Systematic Review on Coronavirus Disease MESHD 2019 (COVID-19)

    Authors: Hira Karim; Muhammad Shahzeb Khan

    id:10.20944/preprints202008.0516.v1 Date: 2020-08-24 Source: Preprints.org

    Emerging and reemerging pathogens is a global challenge for public health. Recently, a novel coronavirus disease MESHD emerged in Wuhan, Hubei province of China, in December 2019. It is named COVID-19 by World Health Organization (WHO). It is known to be caused by Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) that affects the lower respiratory tract and manifests as pneumonia HP pneumonia MESHD in humans. Coronaviruses (CoVs) are structurally more complicated as compared to other RNA viruses. This viral epidemic has led to the deaths of many, including the elderly TRANS or those with chronic disease MESHD or compromised immunity. Viruses cause infection MESHD and diseases in humans of varying degrees, upper respiratory tract infections MESHD respiratory tract infections HP ( URTIs MESHD) cause common cold while lower respiratory tract infections HP induce pneumonia HP pneumonia MESHD, bronchitis HP bronchitis MESHD, and even severe acute respiratory syndrome MESHD (SARS). The costs of COVID-19 are not limited. It equally affects all the medical, sociological, psychological, and economic aspects globally. This is regarded as the third deadly outbreak in the last two decades after Severe Acute Respiratory Syndrome SARS MESHD (2002–2003) and Middle East Respiratory Syndrome MERS MESHD (2012). Based on the sequence homology of SARS-CoV-2, different animal sources including bats, snakes, and pangolins have been reported as potential carriers TRANS of this viral strain. Real-time RT-PCR represents the primary method for the diagnosis of new emerging viral strain SARS-CoV-2. The transmission TRANS dynamics suggest that SARS-CoV-2 is transmitted from person-to-person through direct contact or coughing HP, sneezing HP, and by respiratory droplets. Several anti-viral treatments including lopinavir/ritonavir, remdesivir, chloroquine phosphate, and abidor are also suggested with different recommendations and prescriptions. Protective and preventive strategies as suggested by various health organization i.e. WHO and US Center for Disease Control and Prevention (CDC) must be adopted by everyone. This review covers the important aspects of novel COVID-19 including characteristics, virology, symptoms, diagnostics, clinical aspects, transmission TRANS dynamics, and protective measures of COVID-19.

    Clinical Course and Management of 73 Hospitalized Moderate Patients with COVID-19 Outside Wuhan

    Authors: Xiaojuan Peng; Qi Liu; Zhaolin Chen; Guiyan Wen; Qing Li; Yanfang Chen; Jie Xiong; Xinzhou Meng; Yuanjin Ding; Ying Shi; Shaohui Tang

    doi:10.21203/rs.3.rs-52239/v1 Date: 2020-08-01 Source: ResearchSquare

    Background: Moderate cases account for the majority in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD and can also progress to severe/critical condition. Here, we investigated the clinical course and management of hospitalized moderate SARS-CoV-2 patients.Methods: The medical records and follow-up data were analyzed from the SARS-CoV-2 patients outside Wuhan.Results: A total of 73 moderate patients (38 men, 35 women) were included, with median age TRANS of 47.0 (38.5-57.5) years. Among them, only one patient (1.4%) died using active treatment to improve symptoms. The median duration of the four main symptoms cough HP, fever HP fever MESHD, chest tightness HP chest tightness MESHD, and fatigue HP fatigue MESHD were about 1-2 weeks; the median duration of the positive nucleic acid test (NAT) results for SARS-CoV-2 was slightly more than 2 weeks; the median hospitalization time was almost four weeks in 72 moderate survivors. The duration of cough HP cough MESHD and fever HP fever MESHD was positively correlated with the duration of the positive NAT results. On admission, 50% had lymphopenia HP lymphopenia MESHD; less than 30% had abnormal blood SERO biochemistry findings involving hyperglycemia HP hyperglycemia MESHD, liver function and myocardial enzymes. At discharge, the laboratory indexes were substantially improved. Two weeks after discharge, 5.6% survivors experienced a recurrence of the positive NAT results. Conclusions: Moderate SARS-CoV-2 patients have a good prognosis by the active treatment. After discharge, it is necessary that moderate survivors undergo at least a 2-week collective medical observation in quarantine places, which can identify and treat a proportion of patients with re-positive NAT results and to prevent the spread of the potential sources of infection MESHD.

    Impact of Corticosteroids and Immunosuppressive Therapies on Symptomatic SARS-CoV-2 Infection MESHD in a Large Cohort of Patients with Chronic Inflammatory Arthritis MESHD Arthritis HP

    Authors: Ennio Giulio Favalli; Serena Bugatti; Catherine Klersy; Martina Biggioggero; Silvia Rossi; Orazio De Lucia; Francesca Bobbio-Pallavicini; Antonella Murgo; Silvia Balduzzi; Roberto Caporali; Carlomaurizio Montecucco

    doi:10.21203/rs.3.rs-51667/v1 Date: 2020-07-31 Source: ResearchSquare

    Background: Prevalence SERO and outcomes of Coronavirus Disease MESHD ( COVID MESHD)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID MESHD-19 in a large cohort of patients with chronic immune-mediated inflammatory arthritis MESHD arthritis HP.Methods: The study was conducted in the arthritis HP arthritis MESHD outpatient clinic at two large Academic Hospitals in the COVID MESHD-19 most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence SERO of Severe Acute Respiratory Syndrome-Coronavirus-2 MESHD nasopharyngeal swab positivity and the occurrence of acute respiratory illness MESHD ( fever HP and/or cough HP and/or dyspnea HP dyspnea MESHD), administered face-to-face or by phone to consecutive patients from 25th February to 20th April 2020. COVID MESHD-19 cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID MESHD-19 incidence was evaluated. Results: The study population included 2050 adults TRANS with chronic inflammatory arthritis MESHD arthritis HP receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs). Laboratory-confirmed COVID MESHD-19 and highly suspicious infection MESHD were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID MESHD-19 (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs were observed.Conclusions: During the COVID MESHD-19 outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection TRANS risk of infection TRANS.Trial registration:  retrospectively registered

    Anesthesia for an emergency gastrorrhagia operation MESHD in a patient suspected with COVID-19: a case report

    Authors: Yu Chen; Hao Lv

    doi:10.21203/rs.3.rs-44673/v1 Date: 2020-07-17 Source: ResearchSquare

    BackgroundThe spread of the  Coronavirus Disease MESHD 2019 (COVID-19) in China since December 2019 was very grave. According to Chinese govenment's guidelines, patients can be divided into confirmed cases TRANS and suspected cases. The protective measures for both are the same.Case summaryWe report a case of an emergency gastrorrhagia MESHD operation for a patient suspected to have contracted COVID-19. A 54-year-old man with massive gastric hemorrhage MESHD was scheduled for an emergency operation for exploratory hemostasis. COVID-19 infection MESHD, however, could not be ruled out, and the patient was treated as a suspected case. All the protective measures were based on patients infected MESHD or suspected to be  infected MESHD with COVID-19. Before the operation, we carried out a series of protective measures, such as preparing the operating room and wearing personal protective gear. We increased the dose of neuromuscular blocking agents during the induction of anesthesia to prevent the splashing of secretions by coughing HP. The operation went smoothly, and the patient was transferred to an intensive care unit (ICU) in the isolation ward for extubation. Seven days later, the patient was ruled out for COVID-19 infection MESHD. ConclusionThe patient recovered successfully from the massive gastric hemorrhage MESHD, and the medical staff were not infected.

    Comparison of Clinical Features on Admission Between Coronavirus Disease MESHD 2019 and Influenza A among Children TRANS: A Retrospective Study in China

    Authors: Feng Liang; Xianfeng Wang; Hui Li; Jun Chen; Lei Liu; Jianbo Shao; Yi Xu; Liya He; Huiying Liang; Kuanrong Li; Sitang Gong; Huimin Xia

    doi:10.21203/rs.3.rs-44748/v1 Date: 2020-07-17 Source: ResearchSquare

    Background: Coronavirus disease 2019 (COVID-19) share similar symptoms with influenza A (IA), but it is more worthwhile to understand the disparities of the two infections regarding their clinical characteristics on admission. Methods: A total of 71 age TRANS-matched pediatric IA and COVID-19 patient pairs were formed and their clinical data on admission were compared. Results: Fever HP Fever MESHD, cough HP cough MESHD, nasal congestion and nausea/vomiting HP nausea/vomiting MESHD vomiting MESHD were the most common symptoms on admission for both infections MESHD but occurred less often in COVID-19. The IA patients were more likely to have lower-than-normal levels of lymphocyte count and percentage and to have higher-than-normal levels of activated partial thromboplastin time, prothrombin time, serum SERO C-reactive protein, and serum SERO procalcitonin, while the COVID-19 patients had higher odds of having lower-than-normal levels of neutrophil count and percentage.Conclusions: This study suggests that influenza A is more symptomatic than COVID-19 for children TRANS and might be an overall more severe infection HP at the time of admission. 

    Sex Differences in an Italian Pediatric Population Covid-19 Positive

    Authors: Elisabetta Straface; Isabella Tarissi De Jacobis; Rosa Vona; Camilla Cittadini; Alessandra Marchesi; Laura Cursi; Lucrezia Gambardella; Alberto Villani

    doi:10.21203/rs.3.rs-44105/v1 Date: 2020-07-16 Source: ResearchSquare

    Background: Since December 2019 coronavirus disease MESHD (COVID-19) emerged in Wuhan and spread rapidly worldwide. Despite the high number of people affected, data on clinical features and prognostic factors in children TRANS and adolescents are limited. We propose a retrospective study aimed to identify sex differences in a pediatric population with COVI-19.Methods: A pediatric population admitted with COVID-19 to Bambino Gesù Children TRANS's Hospital of Rome (Italy) in the period from March to May 2020 has been studied taking into account sex differences. Medical history, comorbidities, symptoms and laboratory findings were obtained from patients' electronic medical records. Results: In 37 patients (19 males TRANS and 18 females TRANS) we found that: i) fever HP fever MESHD and cough HP cough MESHD were the dominant symptoms, while gastrointestinal symptoms were rare; and ii) all ages TRANS of childhood were susceptible to COVID-19. Moreover, we found that females TRANS with COVID-19 were older than males TRANS (p < 0.01); required more days of hospitalization (p < 0.04); needed of treatment with multiple drugs; and had higher serum SERO lactate dehydrogenase values (p < 0.04) than males TRANS. Conversely, males TRANS had, although not significant, higher values of C reactive protein and erythrocyte sedimentation rate than females TRANS.Conclusions: Based on the data listed above sex differences were detected in an Italian pediatric population. Compared to the adults TRANS we found that COVID-19 infection MESHD in children TRANS is a non-severe inflammatory disease MESHD in both males TRANS and females TRANS. In any case, many detailed studies should be conducted. 

    Optimized Laboratory Detection Strategy for COVID-19 Patients Reduces the Rate of Missed Diagnosis

    Authors: Wenjiao Chang; Yuru Shi; Yingjie Qi; Jiaxing Liu; Ting Liu; Zhaowu Chen; Dongfeng Liu; Ming Yin; Jing Xu; Yun Yang; Jing Ge; Shu Zhu; Yong Gao; Xiaoling Ma

    doi:10.21203/rs.3.rs-42485/v1 Date: 2020-07-13 Source: ResearchSquare

    Background: Novel coronavirus pneumonia MESHD pneumonia HP (NCP) is an emerging, highly contagious community acquired pneumonia HP pneumonia MESHD (CAP) caused by severe acute SARS-CoV-2. Nucleic acid test currently played a crucial role in diagnosis of suspected COVID-19 patients. However, a high false-negative rate of this “gold standard” test has been reported and posed a major setback in blocking the spread of the virus. We here aim to describe an optimized laboratory detection strategy to reduce the false negative rate. Methods: Suspected NCP patients were asked to collect both coughed HP up specimen and pharyngeal swab. Samples from the same patient were mixed and tested at a single pool. SARS-CoV-2 was then detected by real-time RT-PCR using two different detection kits. Only if both results were negative was the test reported as negative. The patients will be excluded after two consecutive negative tests at 24 hour intervals. We also used multiplex PCR to detect 13 common respiratory tract pathogens (RTP). Results: Using this strategy, we confirmed 85 SARS-CoV-2 infections MESHD from 181 suspected patients, and 94.12% of patients were positive in the first test. The 96 excluded patients were followed up, and no additional NCP was found. We also found that 31.25% patients in 96 non-NCP patients were infected MESHD with at least one RTP that may cause CAP. Conclusion: Our studies suggest that dual reagents screening with pooled coughed HP up specimen and pharyngeal swab samples reduced the false negative rate of nucleic acid testing. During the epidemic of NCP in Anhui province, there was a certain proportion of infection and co-infection MESHD of other common pathogens of CAP. In comparison with SARS-CoV-2 detection alone, combining multiple pathogen detection reduces the rate of miss diagnosis.

    Recovery of moderate COVID-19 disease in a liver transplant recipient on continued immunosuppression

    Authors: Victor Dahl Mathiasen; Stine Karlsen; Peter Ott; Søren Jensen-Fangel; Steffen Leth

    doi:10.21203/rs.3.rs-39120/v1 Date: 2020-06-29 Source: ResearchSquare

    BackgroundThe global outbreak of severe acute respiratory syndrome coronavirus 2 MESHD has had an enormous impact on the world. It remains unclear to what extent liver transplant recipients should be considered at a higher risk of severe disease due to the limited data available.Case presentationWe describe a moderate course of COVID-19 in a patient who underwent a liver transplant two years earlier due to Budd-Chiari syndrome HP Budd-Chiari syndrome MESHD. She presented with malaise MESHD, headache HP headache MESHD, dry cough MESHD cough HP and fever HP fever MESHD for four days. Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection MESHD, oxygen therapy was given for a single night and the patient gradually recovered with supportive care only.ConclusionsWith this case report, we demonstrate that liver transplantation and immunosuppression is not necessarily associated with severe COVID-19 disease and emphasize that more information on this matter is urgently required. Withdrawal of immunosuppressive therapy could be associated with a higher mortality.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.